This study won the clinical site team award in the Pharma Times Clinical Research Awards 2021, as well as the NIHR Yorkshire and Humber Research Awards for Outstanding Contribution to COVID-19 Research 2022.
The PROVENT Antibody Trial investigated monoclonal antibodies which were developed to help prevent COVID-19 infection, and to suppress the severity in infected patients. The study was particularly targeted towards people who were extremely vulnerable to COVID-19 (due to immunosuppression or underlying conditions), or at an increased risk of exposure to the virus due to living or working circumstances.
Analysis of the study showed that the antibody combination used in this trial (Evusheld) reduced the risk of COVID-19 by around 77% in the sample population.
In 2022, this was licensed for the prevention of COVID-19 in vulnerable groups.
This study was delivered by the Wakefield Research Partnership on behalf of AstraZeneca.
The partnership includes Spectrum Community Health CIC, Mid Yorkshire Hospitals NHS Trust, Conexus Healthcare, South West Yorkshire Partnership NHS Foundation Trust, Wakefield Council, Yorkshire Ambulance Service, National Institute for Health and Care Research (NIHR) Yorkshire and Humber Clinical Research Network, Bradford and Craven Clinical Commissioning Group.